Association between procalcitonin levels and duration of mechanical ventilation in COVID-19 patients

Martin Krause¹, David J. Douin¹, Timothy T. Tran¹, Ana Fernandez-Bustamante¹, Muhammad Aftab², Karsten Bartels¹,²*

¹ Department of Anesthesiology, University of Colorado, School of Medicine, Aurora, Colorado, United States of America, ² Department of Surgery, University of Colorado, School of Medicine, Aurora, Colorado, United States of America

* karsten.bartels@ucdenver.edu

Abstract

Background

Patients diagnosed with COVID-19 frequently require mechanical ventilation. Knowledge of laboratory tests associated with the prolonged need for mechanical ventilation may guide resource allocation. We hypothesized that an elevated plasma procalcitonin level (>0.1 ng/ml) would be associated with the duration of invasive mechanical ventilation.

Methods

Patients diagnosed with COVID-19, who were admitted to any of our health system’s hospitals between March 9th-April 20th, 2020 and required invasive mechanical ventilation, were eligible for this observational cohort study. Demographics, comorbidities, components of the Sequential Organ Failure Assessment score, and procalcitonin levels on admission were obtained from the electronic health record. The primary outcome was the duration of mechanical ventilation; secondary outcomes included 28-day mortality and time to intubation. Outcomes were assessed within the first 28 days of admission. Baseline demographics and comorbidities were summarized by descriptive statistics. Univariate comparisons were made using Pearson’s chi-square test for binary outcomes and Mann-Whitney U test for continuous outcomes. A multiple linear regression was fitted to assess the association between procalcitonin levels and the duration of mechanical ventilation.

Results

Patients with an initial procalcitonin level >0.1 ng/ml required a significantly longer duration of mechanical ventilation than patients with a level of ≤0.1 ng/ml (p = 0.021) in the univariate analysis. There was no significant difference in 28-day mortality or time to intubation between the two groups. After adjusted analysis using multivariable linear regression, the duration of mechanical ventilation was, on average, 5.6 (p = 0.016) days longer in patients with an initial procalcitonin level >0.1 ng/ml.
Conclusion
In this cohort of 93 mechanically ventilated COVID-19 patients, we found an association between an initial plasma procalcitonin level >0.1 ng/ml and the duration of mechanical ventilation. These findings may help to identify patients at risk for prolonged mechanical ventilation upon admission.

Introduction
Since the initial outbreak in the Hubei Province of China in November 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread around the world and was declared a pandemic by the World Health Organization [1, 2]. Based on observational studies from the epicenters of the pandemic in Wuhan, China, the Lombardy region in Italy, and the New York City area in the United States, a significant portion of patients diagnosed with coronavirus disease 2019 (COVID-19) were admitted to the intensive care unit (ICU) for ventilatory support: Between 17%-24% of hospitalized patients and up to 72% of patients admitted to the ICU have required invasive mechanical ventilation [2–5]. While most ventilated patients fulfill the Berlin Definition for acute hypoxemic respiratory distress syndrome, the unique and variable clinical course of COVID-19 has made it difficult to predict the disease’s progression [6, 7].

Laboratory values, including plasma C-reactive protein, D-dimer, lactate dehydrogenase, and procalcitonin, are often elevated in patients with COVID-19 who required ICU-admission, mechanical ventilation, or died [8–11]. Knowledge of laboratory tests associated with prolonged mechanical ventilation and mortality in a health care environment constrained by high demand and limited resources, especially regarding ventilatory support, is critical. In a critically ill COVID-19 cohort from a large United States healthcare system, we hypothesized that elevated plasma procalcitonin levels would be associated with a longer duration of mechanical ventilation.

Materials and methods
Ethical approval was obtained from the Institutional Review Board (Colorado Multiple Institutional Review Board #20–0677) on April 3rd, 2020, and the requirement for informed consent was waived. Data were collected retrospectively for any events before April 3rd, and prospectively going forward. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting observational studies [12].

Aim, design, and setting
We aimed to identify if plasma procalcitonin levels on admission are associated with the duration of mechanical ventilation (primary outcome), 28-day mortality, and time to intubation (secondary outcomes) in a cohort of COVID-19 patients requiring mechanical ventilation. We designed an observational cohort study using automated data collection and manual chart review from the Electronic Health Record (EHR) from 12 hospitals within a large United States health care system.
Participants, covariates, and outcomes

Patients with COVID-19 that were admitted between 03/09/2020 and 04/20/2020 to one of the health system’s ICUs requiring mechanical ventilation were eligible for inclusion in this study [13]. Exclusion criteria were age <18 years, patients’ or their proxies’ objection to observational data collection for research, or no procalcitonin level drawn during the admission (Fig 1).

Patient characteristics including relevant baseline demographics, chronic comorbidities, components of the Sequential Organ Failure Assessment (SOFA) score, and procalcitonin

93 patients with COVID-19:
- admitted between March 9, 2020 and April 20, 2020 at one of 12 hospitals of the University of Colorado Health Care System
- requiring mechanical ventilation

Exclusion criteria:
- age <18 years
- patients or proxy objected to observational data collection for research
- no procalcitonin drawn on patient during admission

15 (16.1%) patients with initial procalcitonin ≤ 0.1 ng/ml
78 (83.9%) patients with initial procalcitonin > 0.1 ng/ml

Characteristics and Outcomes:
- demographics: age in years, gender, body mass index (BMI), race, ethnicity, and insurance
- chronic comorbidities: cardiac disease, pulmonary disease, hypertension, diabetes mellitus, renal disease, liver disease, history of a solid malignant tumor
- Sequential Organ Failure Assessment (SOFA) score, procalcitonin
- duration of mechanical ventilation
- 28-day mortality
- time from admission to intubation

Univariate Analysis:
- duration of mechanical ventilation
- 28-day mortality

Multivariate Regression Analysis:
- age
- BMI
- SOFA score
- procalcitonin
- diabetes mellitus
- chronic cardiac disease
- hypertension
levels were obtained from the EHR. Demographics included: age in years, self-reported gender, body mass index (BMI) in kg/m$^2$, race, ethnicity, and insurance status. We chose chronic comorbidities according to previously reported findings from our group [13] and others [10, 14] based on relevant pre-existing International Classification of Diseases codes (ICD-10) information from the EHR. Comorbidities were comprised of any history of cardiac disease, pulmonary disease, hypertension, diabetes mellitus, renal disease, liver disease, and solid malignancies. To calculate the SOFA score at hospital admission, we used the first drawn platelet count, creatinine, and bilirubin, the first recorded Glasgow Coma Scale score, and the lowest mean arterial pressure or the highest dose of vasoactive agents within the first eight hours of admission [15]. Furthermore, we obtained the first drawn procalcitonin level during the index admission. In-hospital mortality within 28 days was assessed based on the date of death as recorded in the EHR. Information on the duration of mechanical ventilation during the first 28 days of admission was obtained using manual chart review. Following published literature [16, 17], days were counted towards invasive mechanical ventilation, if the patient was mechanically ventilated within the first 28 days of admission, if a patient was reintubated within 48 hours (failure to extubate), or if a patient with a tracheostomy was on noninvasive ventilation or not requiring invasive/noninvasive ventilation for less than 48 hours (failure to wean). Furthermore, a patient who died within the first 28 days of admission was accounted for 28 days of invasive mechanical ventilation [16, 17]. The day of admission accounted for day 1 to assess time from admission to intubation and time from admission to death.

**Statistical analysis**

Results were summarized using descriptive statistics, and continuous data were assessed for normality of distribution. Univariate comparisons were performed using Mann-Whitney U tests for continuous outcomes, and Pearson’s chi-square test for the binary mortality outcome. We then assessed if there was an association between an initial procalcitonin level of >0.1 ng/ml [18] vs. less and the duration of mechanical ventilation by fitting a linear regression model. Age, BMI, hypertension, diabetes mellitus, chronic cardiac disease, SOFA score on admission, and the first available procalcitonin level during the hospitalization were chosen as covariates in the model. Statistical analysis was performed using the software program SPSS, Version 26 (IBM Corporation, Armonk, NY).

A basic power analysis for a linear multiple regression model was performed using G*Power, version 3.1.9.2 [19]. Imputing an effect size $f^2$ of 0.15, the number of tested predictors as 1, and the total number of predictors as 4, an alpha = 0.05 and a desired power of 90%, the sample size required would have been $n = 73$.

**Results**

A total of 93 mechanically ventilated patients who tested positive for COVID-19 and had a procalcitonin level on file were included. The median duration of mechanical ventilation was 14 days. Patients’ demographics and comorbidities, SOFA scores on admission, initial procalcitonin levels, and outcomes are summarized in Table 1.

In the univariate analysis, patients with an initial procalcitonin level >0.1 ng/ml had a median duration of 17 days mechanical ventilation compared to patients with an initial procalcitonin level ≤0.1 ng/ml, who had a median duration of 10 days ($p = 0.021$) (Table 2). There was no significant difference in duration of mechanical ventilation for patients with a procalcitonin level >0.25 ng/ml vs. lower or >0.5 ng/ml vs. lower. There was also no significant difference in 28-day mortality or time from admission to intubation for patients with a
Table 1. Demographics, comorbidities, and outcomes.

| Characteristic                          | Frequency |
|----------------------------------------|-----------|
| Total                                  | 93 (100)  |
| Gender                                 |           |
| Men                                    | 62 (66.7) |
| Women                                  | 31 (33.3) |
| Race                                   |           |
| Caucasian or White                     | 44 (47.3) |
| African American or Black              | 23 (24.7) |
| Multiple races or other                | 26 (28.0) |
| Ethnicity                              |           |
| Hispanic                               | 31 (33.3) |
| Not Hispanic                           | 62 (66.7) |
| Insurance status                       |           |
| Managed care                           | 33 (35.5) |
| Medicare                               | 35 (37.6) |
| Medicaid, self pay, indigent, or other | 25 (26.9) |
| Chronic cardiac disease                |           |
| Yes                                    | 41 (44.1) |
| No                                     | 52 (55.9) |
| Hypertension                           |           |
| Yes                                    | 69 (74.2) |
| No                                     | 24 (25.8) |
| Chronic pulmonary disease              |           |
| Yes                                    | 39 (41.9) |
| No                                     | 54 (58.1) |
| Diabetes mellitus                      |           |
| Yes                                    | 37 (39.8) |
| No                                     | 56 (60.2) |
| Preexisting renal disease              |           |
| Yes                                    | 28 (30.1) |
| No                                     | 65 (69.9) |
| Chronic liver disease                  |           |
| Yes                                    | 18 (19.4) |
| No                                     | 75 (80.6) |
| History of solid malignant tumor       |           |
| Yes                                    | 11 (11.8) |
| No                                     | 82 (88.2) |
| Procalcitonin level >0.5 ng/ml         |           |
| Yes                                    | 25 (26.9) |
| No                                     | 68 (73.1) |
| Procalcitonin level >0.25 ng/ml        |           |
| Yes                                    | 42 (45.2) |
| No                                     | 51 (54.8) |
| Procalcitonin level >0.1 ng/ml         |           |
| Yes                                    | 78 (83.9) |
| No                                     | 15 (16.1) |

| Characteristic | Mean |
|----------------|------|
| Age–years      | 59 (15) |

(Continued)
procalcitonin level $>0.1$ ng/ml vs. lower (Table 2). In deceased patients with an initial procalcitonin level $>0.1$ ng/ml, death occurred at a median duration of 11 days.

The results from a fitted multivariable linear regression model with the duration of mechanical ventilation in days as the dependent variable are presented in Table 3. After adjustment for age, BMI, chronic cardiac disease, diabetes mellitus, hypertension, and SOFA score on admission, the multivariable linear regression model demonstrated that the duration of mechanical ventilation was on average 5.6 days (95% confidence interval 1.09–10.17, $p = 0.016$) longer in patients with an initial procalcitonin level $>0.1$ ng/ml compared to those with a lower procalcitonin level. In addition, older age (B = 0.22, 95% confidence interval 0.10–0.35, $p = 0.001$) and higher BMI (B = 0.23, 95% confidence interval 0.02–0.43, $p = 0.033$) were associated with a longer duration of mechanical ventilation. The other independent variables included in the regression model were not significantly associated with the duration of mechanical ventilation.

**Discussion**

In the univariate analysis of our observational cohort study, procalcitonin levels $>0.1$ ng/ml on admission were associated with prolonged mechanical ventilation in critically ill COVID-19 patients. The multiple linear regression model revealed that the duration of mechanical ventilation was, on average, 5.6 days longer in patients with an initial procalcitonin level $>0.1$ ng/ml.
Our findings demonstrate an association between elevated procalcitonin levels on admission and duration of mechanical ventilation in patients with COVID-19, thereby affirming our hypothesis. Given a shortage of ventilators in epicenters of this pandemic and the association between limited resources and COVID-19 mortality, we view our findings as highly relevant [20, 21]. In addition, prolonged mechanical ventilation is associated with ICU-acquired weakness and neurocognitive decline, which both contribute to short- and long-term mortality [22, 23].

Early studies from China identified an elevated procalcitonin level as a predictor of the severity of COVID-19 infections but did not specifically explore an association between procalcitonin and duration of mechanical ventilation [3, 9, 11]. Procalcitonin is currently used to predict treatment failure and mortality in lower respiratory infections [24]. However, its plasma level often remains within the normal range in non-complicated cases of COVID-19. It has, therefore, been suggested as a helpful early marker of bacterial superinfections and disease progression [25]. Indeed, mechanically ventilated COVID-19 patients are more likely to suffer from bacteremia [26]. Identifying patients with COVID-19 who are at risk for prolonged mechanical ventilation may assist clinicians in allocating scarce resources and aid in patients’ risk stratification.

Our multivariate regression analysis was adjusted for severity of disease by including the SOFA score, for predisposing characteristics by including age, BMI, diabetes mellitus, hypertension, and chronic cardiac disease, and for procalcitonin levels on admission based on our own preliminary findings and other literature [8–11, 13, 27–29]. Besides a procalcitonin level of >0.1 ng/ml, duration of mechanical ventilation was associated with age and BMI in our multivariate regression model. Indeed, early literature from China and Europe identified age and obesity as risk factors for invasive mechanical ventilation [2, 7, 14, 30]. We did not find a correlation between elevated procalcitonin levels and 28-day mortality. However, 17 of 18 patients who died (94.4%) showed an elevated procalcitonin level suggesting that appropriately powered retro- or prospective studies might be able to identify such an association.

**Limitations**

Our study has multiple weaknesses: First, an observational cohort study is not designed as a randomized controlled trial, and residual confounding remains possible [31]. For example, exclusion of patients without a documented procalcitonin level may have induced a selection bias. However, only three patients were excluded due to the lack of laboratory testing. Furthermore, our findings may not be representative of other areas of the United States or other countries. Lastly, prolonged mechanical ventilation and in-hospital mortality were determined.

---

**Table 3. Linear regression analysis for days mechanically ventilated as the dependent variable.**

| Characteristic                      | B coefficient | 95% confidence limit | p-value |
|------------------------------------|---------------|----------------------|---------|
| Intercept                          | -7.04         | -19.45, 5.37         | 0.263   |
| Age (years)                        | 0.22          | 0.10, 0.35           | 0.001   |
| Body mass index (kg/m²)            | 0.23          | 0.02, 0.43           | 0.033   |
| Chronic cardiac disease (y/n)      | -2.12         | -5.73, 1.50          | 0.247   |
| Diabetes mellitus (y/n)            | 1.29          | -2.38, 4.95          | 0.487   |
| Hypertension (y/n)                 | -1.04         | -5.29, 3.22          | 0.630   |
| Sequential Organ Failure Assessment score | -0.05     | -1.05, 0.95          | 0.921   |
| Procalcitonin >0.1 ng/ml (y/n)     | 5.63          | 1.09, 10.17          | 0.016   |

Overall model significance was p = 0.006 with seven degrees of freedom.

https://doi.org/10.1371/journal.pone.0239174.t003
within 28 days of the patient’s admission. A later follow-up could potentially show significant associations between demographics, comorbidities, and laboratory values in either of our outcomes, which were not identified at 28 days. Given the need for additional timely information during this pandemic as well as previous work by others [16, 17], we chose 28 days as the cut-off time-point for this study.

Conclusions

Our observational study including 93 critically ill COVID-19 patients requiring mechanical ventilation found an association between a procalcitonin value of >0.1 ng/ml on admission and the duration of mechanical ventilation. Procalcitonin could be used to risk-stratify mechanically ventilated COVID-19 patients.

Author Contributions

Data curation: Martin Krause, David J. Douin, Timothy T. Tran, Ana Fernandez-Bustamante, Karsten Bartels.

Formal analysis: Martin Krause, Karsten Bartels.

Funding acquisition: Karsten Bartels.

Supervision: Karsten Bartels.

Writing – original draft: Martin Krause, Karsten Bartels.

Writing – review & editing: Martin Krause, David J. Douin, Timothy T. Tran, Ana Fernandez-Bustamante, Muhammad Aftab, Karsten Bartels.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727–33. https://doi.org/10.1056/NEJMoa2001017 PMID: 31978945
2. Grasselli G, Zangrillo A, Zanello A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; https://doi.org/10.1001/jama.2020.5394 PMID: 32250385
3. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; https://doi.org/10.1001/jamacardio.2020.1017 PMID: 32219366
4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3 PMID: 32171076
5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020; https://doi.org/10.1001/jama.2020.6775 PMID: 32320003
6.Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020; 24(1):154. https://doi.org/10.1186/s13054-020-02880-z PMID: 32299472
7. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020; https://doi.org/10.1001/jamainternmed.2020.0994 PMID: 32167524
8. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032 PMID: 32109013
9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 PMID: 31986264
10. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA: the journal of the American Medical Association. 2020; https://doi.org/10.1001/jama.2020.1585 PMID: 32031570

11. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020; 75(7):1730–41. https://doi.org/10.1111/all.14238 PMID: 32077115

12. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. International journal of surgery. 2014; 12(12):1495–9. https://doi.org/10.1016/j.ijssu.2014.07.013 PMID: 25046131

13. Krause M, Donin D, Kim K, Fernandez-Bustamente A, Bartels K. Characteristics and Outcomes of Mechanically Ventilated COVID-19 Patients—an Observational Cohort Study. Intensive Care Med. 2020; https://doi.org/10.1007/s00134-020-06116-8 PMID: 32731033

14. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity (Silver Spring). 2020; https://doi.org/10.1002/oby.22831 PMID: 32271993

15. Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score-development, utility and challenges of accurate assessment in clinical trials. Crit Care. 2019; 23(1):374. https://doi.org/10.1186/s13054-019-2663-7 PMID: 31775846

16. Yehya N, Harhay MO, Curley MAQ, Schoenfeld DA, Reeder RW. Reappraisal of Ventilator-Free Days in Critical Care Research. Am J Respir Crit Care Med. 2019; 200(7):826–36. https://doi.org/10.1164/ rccm.201810-219OC PMID: 31034248

17. Schoenfeld DA, Bernard GR, Network A. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002; 30 (6):1772–7. https://doi.org/10.1097/00003246-200206000-00016 PMID: 12163791

18. Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med. 2014; 190(10):1102–10. https://doi.org/10.1164/rccm.201408-1483OC PMID: 25295709

19. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behavior research methods. 2009; 41(4):1149–60. https://doi.org/10.3758/BRM.41.4.1149 PMID: 19897623

20. Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and healthcare resource availability. Lancet Glob Health. 2020; 8(4):e480.

21. Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages—The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic. N Engl J Med. 2020; 382(24):2372–4. https://doi.org/10.1056/NEJM p2006141 PMID: 32212516

22. Barr J, Fraser GL, Puntillo K, Ely EW, Gelinas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013; 41(1):263–306. https://doi.org/10.1097/CCM.0b013e3182783b72 PMID: 23269131

23. Hermans G, Van den Berge G. Clinical review: intensive care unit acquired weakness. Crit Care. 2015; 19:274. https://doi.org/10.1186/s13054-015-0993-7 PMID: 26242743

24. Kutz A, Briel M, Christ-Crain M, Stolz D, Boudadma L, Wolff M, et al. Prognostic value of procalcitonin in respiratory tract infections across clinical settings. Crit Care. 2015; 19:74. https://doi.org/10.1186/ s13054-015-0792-1 PMID: 25887979

25. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020; 505:190–1. https://doi.org/10.1016/j.cca.2020.03.004 PMID: 32145275

26. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020; 382(24):2372–4. https://doi.org/10.1056/NEJMc2010419 PMID: 32302078

27. Simonnet A, Chetboun M, Poissy J, Raverdy V, Nourlette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020; https://doi.org/10.1002/oby.22831 PMID: 32271993

28. Yancy CW. COVID-19 and African Americans. JAMA. 2020; https://doi.org/10.1001/jama.2020.6548 PMID: 32293639

29. Gupta E, Hossen S, Grigsby MR, Herrera P, Roldan R, Paz E, et al. Risk factors for the development of acute respiratory distress syndrome in mechanically ventilated adults in Peru: a multicenter observational study. Crit Care. 2019; 23(1):398. https://doi.org/10.1186/s13054-019-2646-8 PMID: 31810487
30. Pan A, Liu L, Wang C, Guo H, Hao X, Wang Q, et al. Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. JAMA. 2020; https://doi.org/10.1001/jama.2020.6130 PMID: 32275295

31. Sedgwick P. Bias in observational study designs: case-control studies. BMJ. 2015; 350:h560. https://doi.org/10.1136/bmj.h560 PMID: 25636996